Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Galmed Pharma (GLMD) Tops Q3 EPS by 8c
November 6, 2019 7:23 AM ESTGalmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.21), $0.08 better than the analyst estimate of ($0.29).
Financial Summary - Third Quarter 2019 vs. Third Quarter 2018:
Cash and cash equivalents, short-term deposits and marketable securities totaled $79.7 million as of September 30, 2019, compared to $90.2 million at December 31, 2018.Net loss of $4.5 million, or ($0.21) per share, for the three months ended September 30, 2019, compared to a net loss of $1.0 million, or ($0.05) per share, for the three months ended September 30, 2018.Research and... More